Histone Deacetylase Inhibitors
"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.
| Descriptor ID |
D056572
|
| MeSH Number(s) |
D27.505.519.389.360
|
| Concept/Terms |
Histone Deacetylase Inhibitors- Histone Deacetylase Inhibitors
- Deacetylase Inhibitors, Histone
- Inhibitors, Histone Deacetylase
- Histone Deacetylase Inhibitor
- Deacetylase Inhibitor, Histone
- Inhibitor, Histone Deacetylase
- HDAC Inhibitors
- Inhibitors, HDAC
|
Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".
This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2001 | 2 | 2 | 4 |
| 2002 | 2 | 2 | 4 |
| 2003 | 2 | 3 | 5 |
| 2004 | 7 | 1 | 8 |
| 2005 | 5 | 8 | 13 |
| 2006 | 7 | 7 | 14 |
| 2007 | 12 | 5 | 17 |
| 2008 | 7 | 5 | 12 |
| 2009 | 10 | 6 | 16 |
| 2010 | 12 | 14 | 26 |
| 2011 | 14 | 5 | 19 |
| 2012 | 8 | 14 | 22 |
| 2013 | 12 | 8 | 20 |
| 2014 | 9 | 6 | 15 |
| 2015 | 9 | 10 | 19 |
| 2016 | 8 | 8 | 16 |
| 2017 | 5 | 6 | 11 |
| 2018 | 4 | 1 | 5 |
| 2019 | 3 | 5 | 8 |
| 2020 | 5 | 4 | 9 |
| 2021 | 2 | 4 | 6 |
| 2022 | 0 | 6 | 6 |
| 2023 | 1 | 1 | 2 |
| 2024 | 5 | 2 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.
-
Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia. Commun Biol. 2024 Oct 04; 7(1):1257.
-
Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. Int J Mol Sci. 2024 Aug 26; 25(17).
-
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML. Nat Commun. 2024 Jun 04; 15(1):4739.
-
Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. Oncotarget. 2024 Jun 03; 15:361-373.
-
Critical Role of histone deacetylase 3 in the regulation of kidney inflammation and fibrosis. Kidney Int. 2024 Apr; 105(4):775-790.
-
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 Apr; 80(4):610-621.
-
ING1 inhibits Twist1 expression to block EMT and is antagonized by the HDAC inhibitor vorinostat. Eur J Cell Biol. 2023 Sep; 102(3):151341.
-
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
-
Development of Human Adrenocortical Adenoma (HAA1) Cell Line from Zona Reticularis. Int J Mol Sci. 2022 Dec 29; 24(1).